William Lazonick, professor emeritus of economics at University of Massachusetts, is co-founder and president of the Academic-Industry Research Network, a 501(c)(3) non-profit research organization, based in Cambridge, Massachusetts. He is an Open Society Fellow and a Canadian Institute for Advanced Research Fellow.Over the past decade, the Institute for New Economic Thinking has funded a number of his research projects.

He has professorial affiliations with SOAS University of London and Institut Mines-Télécom in Paris. Previously, Lazonick was assistant and associate professor of economics at Harvard University, professor of economics at Barnard College of Columbia University, and distinguished research professor at INSEAD in France. Lazonick earned his B.Com. at the University of Toronto, M.Sc. in Economics at London School of Economics, and Ph.D. in Economics at Harvard University. He holds honorary doctorates from Uppsala University and the University of Ljubljana.

His research focuses on the social conditions of innovation and economic development in advanced and emerging economies. His book Sustainable Prosperity in the New Economy? Business Organization and High-Tech Employment in the United States (Upjohn Institute 2009) won the 2010 Schumpeter Prize. He has twice—in 1983 and 2010—had the award from Harvard Business School for best article of the year in Business History Review. In 2014, he received the HBR McKinsey Award for outstanding article in Harvard Business Review for “Profits Without Prosperity: Stock Buybacks Manipulate the Market and Leave Most Americans Worse Off.” In January 2020, Oxford University Press published his book, co-authored with Jang-Sup Shin, Predatory Value Extraction: How the Looting of the Business Corporation Became the U.S. Norm and How Sustainable Prosperity Can Be Restored.

By this expert

Setting Pharmaceutical Drug Prices: What the Medicare Negotiators Need to Know About Innovation and Financialization

Paper Working Paper | | Sep 2024

Medicare negotiators need to have a deep understanding - both theoretical and empirical - of the learning processes involved in developing a drug to negotiate a price that is fair.

What Is a “Fair” Drug Price?

Article | Sep 22, 2024

Medicare Needs a Perspective on “Collective and Cumulative Learning” in Inflation Reduction Act Negotiations

Musk and Tesla: Corporate Compensation, Financialization, and the Problem of Strategic Control

Article | Sep 13, 2024

From the perspective of innovative enterprise, we ask how Musk might abuse his power of strategic control—and what that would mean for corporate governance reform.

Tesla as a Global Competitor: Strategic Control in the EV Transition

Paper Working Paper | | Sep 2024

As the “Technoking” of Tesla strategizes to maintain his control over the company’s decision-making, anyone concerned with the role that Tesla will play in the evolving EV transition should be asking how CEO Musk might use, or abuse, his powerful position.

Featuring this expert

Economists Warn: Trump’s Intel Move Looks Like Performance, Not Policy

Article | Aug 26, 2025

Two economists who have studied Intel warn that Trump’s move to take a stake in the company amounts to flashy optics, incoherent strategy, and a creeping politicization of economic policy.

The Fall of Intel

Video | Aug 20, 2025

How America’s chip leader lost its edge.

Elon Musk and Tesla Shape America’s Future. But Problems Run Deeper Than Tweets.

Article | Sep 19, 2024

The financialization of U.S. firms making critical products endangers both American global leadership and, in Tesla’s case, climate change progress.

How Shareholder Value Fixation Turns AI and Robotics into a Recipe for Failure

Article | Sep 11, 2023

New technologies are not the problem. It’s a system distorted by a flawed ideology.